Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 2-year history of seasonal allergic rhinitis~* Positive skin test response to a local seasonal allergen (current, or performed in investigator's office within the past year)~* Good health and free of any unstable, clinically significant disease, other than allergic rhinitis, that would interfere with the study schedule or evaluation of seasonal allergic rhinitis~Exclusion Criteria:~* Women who are pregnant or breastfeeding~* Women of childbearing potential who are not using an acceptable form of birth control~* Significant history of metabolic, cardiovascular, neurologic, hematologic, hepatic, gastrointestinal, cerebrovascular, respiratory, or renal disease, or any other disorder which, in the judgment of the investigator, could interfere with the study, or require treatment which might interfere with the study~* Use of any chronic medication which could affect the course of seasonal allergic rhinitis~* Asthma requiring chronic use of inhaled or systemic corticosteroids (inhaled bronchodilators are permitted for asthma treatment)~* Current or history of frequent, clinically significant sinusitis or chronic purulent postnasal drip~* Upper respiratory tract or sinus infection that requires antibiotic therapy within the previous 2 weeks, or a viral upper respiratory infection (URI) within the 7 days prior to Screening~* Dependence upon nasal, oral or ocular decongestants, or nasal topical antihistamines, in the opinion of the investigator~* Has rhinitis medicamentosa~* Evidence of clinically significant nasal candidiasis~* Investigational drug use within the previous 30 days~* Nasal structural abnormalities, including large nasal polyps and marked septal deviation, that significantly interfere with nasal air flow~* Immunotherapy (desensitization therapy), unless on a stable maintenance schedule for at least one month prior to the Screening visit~* History of multiple drug allergies, allergy to antihistamines or corticoids~* History of psychosis, antagonistic personality, poor motivation, hypochondriasis, or any other emotional or intellectual problems that are likely to limit the validity of consent to participate in the study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MFNS 200 µg + Loratadine 10 mg (Type: EXPERIMENTAL): Daily administration of 200 µg of MFNS plus oral dose of 10 mg loratadine tablet.
- MFNS 200 µg (Type: ACTIVE_COMPARATOR): Daily administration of 200 µg of MFNS plus oral placebo tablet.
- Loratadine 10 mg (Type: ACTIVE_COMPARATOR): Daily administration of oral dose of 10 mg loratadine tablet plus placebo nasal spray.
- Placebo (Type: PLACEBO_COMPARATOR): Daily administration of placebo nasal spray plus oral placebo tablet.

Based on this trial design, predict the completion outcome and termination type (if applicable).